MedWatch

Vaccine against dust mite allergy moving closer

The first of two pivotal phase III studies with a new vaccine tablet against house dust mite allergy from Danish ALK delivers positive results, which opens the door for submitting an application for marketing approval in the EU in 2014.

Foto: ALK-Abelló / PR

A part of the largest development program in the history of the Danish company ALK is coming to an end, after the company announced yesterday that the first of two pivotal phase III studies with a new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases, Mitizax, has been concluded with positive results.

The MERIT trial met its primary end-points, as the results demonstrated that the treatment has a significant clinical effect on so-called allergic rhinitis. The positive results make it possible for the company to submit an application for marketing approval to the European authorities in 2014, according to a press release.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier